Physician profile
Barbara Hirsch
NPI 1679533434
$746,453.32
in general payments reported to CMS, 2019-2025
31 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150K · 2020: $97K · 2021: $81K · 2022: $119K · 2023: $109K · 2024: $120K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200K · Travel and Lodging: $50K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $26K · Consulting Fee: $15K · Food and Beverage: $8,002 · Long Term Medical Supply Or Device Loan: $84.96 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $199,981.25 |
| Travel and Lodging | $49,943.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $26,312.50 |
| Consulting Fee | $15,478.13 |
| Food and Beverage | $8,002.07 |
| Long Term Medical Supply Or Device Loan | $84.96 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $487,494.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $163,870.20 | 2019-2025 | Freestyle Libre 3, Freestyle Libre Pro, Freestyle Libre |
| Novo Nordisk INC | $67,098.23 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Eli Lilly and Company | $7,121.44 | 2024 | |
| Janssen Pharmaceuticals, INC | $6,884.61 | 2019 | |
| Merck Sharp & Dohme LLC | $4,800.38 | 2019 | |
| Cequr Corporation | $3,562.50 | 2023 | Cequr Simplicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,528.33 | 2019-2020 | |
| Abbvie INC. | $2,112.32 | 2019-2024 | |
| Amgen INC. | $194.67 | 2019-2025 | Tepezza, Evenity, Repatha |
| Xeris Pharmaceuticals, INC. | $146.20 | 2020-2024 | Recorlev, Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $106.73 | 2019-2024 | |
| Mannkind Corporation | $78.23 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $60.54 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $59.97 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $45.49 | 2023-2024 | Unithroid |
| Avvisto Therapeutics, LLC | $35.89 | 2024 | Cycloset |
| Astrazeneca Pharmaceuticals LP | $29.17 | 2019-2020 | |
| Corcept Therapeutics | $26.30 | 2023 | Korlym |
| Zealand Pharma US, INC. | $24.66 | 2022 | |
| Medtronic, INC. | $22.35 | 2023 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $20.35 | 2023 | Strensiq |
| Valeritas, INC. | $16.62 | 2019 | |
| Ferring Pharmaceuticals INC. | $16.27 | 2019 | |
| Lifescan, INC. | $16.18 | 2020 | |
| Astellas Pharma US INC | $15.27 | 2023 | Veozah |
| Medtronic Minimed, INC. | $14.93 | 2019 | |
| Insulet Corporation | $13.36 | 2019 | |
| Esperion Therapeutics, INC. | $13.33 | 2020 | |
| Antares Pharma, INC. | $13.15 | 2024 | Xyosted |
| Arbor Pharmaceuticals, INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Hirsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.